Drug Profile
Research programme: microbiome therapeutics - Bristol-Myers Squibb/Sirenas Marine Discovery
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Sirenas Marine Discovery
- Developer Bristol-Myers Squibb; Sirenas Marine Discovery
- Class
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified